Eight Weeks Pregnant and Well on Sertraline: Weighing Relapse Against Fetal Risk With Cohort Data on Discontinuation, Cardiac Defects and Pulmonary Hypertension
[Student Name]
University of Phoenix
PMH/502: Neuropsychiatric Pharmacology
Week 8 Assignment
[Instructor Name]
[Date]
The patient is a composite written for a model paper.
Ms. C., a 31-year-old accountant, has had two episodes of major depression, the second severe with suicidal thoughts. She has been well for 18 months on sertraline 100 mg daily. She has just learned she is eight weeks pregnant and asks, frightened, whether she should stop sertraline immediately. This paper describes our discussion.
The Risk of Stopping
Cohen et al. (2006) followed 201 pregnant women with a history of major depression who were euthymic on antidepressants at conception. Among women who continued medication throughout pregnancy, 26% relapsed, compared with 68% of those who discontinued, and discontinuation was associated with a fivefold higher hazard of relapse. The authors concluded that pregnancy is not protective against relapse. Untreated depression in pregnancy is associated with poor self-care, poor nutrition, substance use and postpartum depression, and Ms. C.'s history of severe depression with suicidal thoughts raises the stakes.
Cardiac Defects
Huybrechts et al. (2014), studying 64,389 women exposed to antidepressants in the first trimester among more than 900,000 pregnancies, found that associations between antidepressant use and cardiac defects weakened with increasing adjustment for confounding and concluded that there was no substantial increase in cardiac malformations attributable to first-trimester antidepressant use.
Persistent Pulmonary Hypertension of the Newborn
Huybrechts et al. (2015) examined antidepressant use late in pregnancy and persistent pulmonary hypertension of the newborn among more than 3.7 million pregnancies. The unadjusted rate was 31.5 per 10,000 births with SSRI exposure compared with 20.8 per 10,000 without; associations weakened with adjustment. The authors concluded that there may be a small increased risk, with a small absolute risk and a more modest increase than earlier studies suggested.
The risks of continuing are small and uncertain; the risk of stopping, for a woman with her history, is large and well measured.
Neonatal Adaptation
Some newborns exposed to SSRIs late in pregnancy show transient symptoms, such as jitteriness, feeding difficulty or breathing changes, usually mild and resolving within days. The pediatric team should know about the exposure.
Putting It Together
The evidence suggests that continuing sertraline carries small risks, while stopping carries a large risk of relapse for a woman with severe recurrent depression. Sertraline has one of the largest bodies of pregnancy safety data among antidepressants and low transfer into breast milk, which matters for breastfeeding later.
Her Decision
After reviewing the numbers, Ms. C. decides to continue sertraline at the current dose. She is relieved to have the data and says she had assumed any medicine would harm the baby. We agree to monitor her mood closely.
Adjusting the Dose in Pregnancy
Sertraline levels can fall later in pregnancy as metabolism increases, so symptoms may return even without stopping. I will check her PHQ-9 at each prenatal visit and consider increasing the dose if symptoms rise.
Why Not Switch to a Different Antidepressant
Switching antidepressants in pregnancy exposes the fetus to two drugs and risks losing a response that took time to achieve. Since sertraline is working and has extensive pregnancy data, switching would add risk without clear benefit.
Why Not Stop Gradually
Some women prefer to taper and stop, hoping to avoid exposure. For those with mild, brief past depression and strong supports, a monitored taper can be reasonable. Ms. C.'s history of severe depression with suicidal thoughts places her in the group for whom continuation is usually recommended, and the relapse data support this (Cohen et al., 2006).
Understanding Absolute Risk
Relative risks can sound frightening. An increase from about 21 to about 32 per 10,000 births in persistent pulmonary hypertension, before adjustment, means that most exposed infants are unaffected, and the adjusted increase was smaller (Huybrechts et al., 2015). Presenting numbers per 10,000 helped Ms. C. see the risk in proportion.
Breastfeeding
She plans to breastfeed. Only tiny quantities of sertraline reach breast milk, and most infants have undetectable levels, making it a preferred antidepressant during breastfeeding.
Her Partner's Role
Her partner attends the next visit. He had also worried about the baby and is reassured by the data. We discuss how he can help her rest and recognize early signs of depression, such as withdrawal, tearfulness or sleeping poorly even when the baby sleeps.
Documentation
The note records her history, the risks discussed with their sources, her decision and the monitoring plan, which supports her care and protects her if others question the decision.
If Symptoms Return
If her PHQ-9 rises above 10 or she has suicidal thoughts, I will see her within days, adjust sertraline and increase therapy frequency. She has the crisis line number and her safety plan from her previous episode.
Sleep in Late Pregnancy and Postpartum
Sleep loss is a strong trigger for depressive relapse after delivery. We plan for her partner to take night feedings with pumped milk on some nights so that she gets longer blocks of sleep.
Mental Health Resources
I give her information about perinatal support groups and a perinatal psychiatry consultation line, which can advise her obstetric team if questions arise.
Preconception Lesson
This pregnancy was unplanned. For future pregnancies, planning ahead allows the decision about medication to be made calmly before conception.
What We Did Not Choose
We did not increase her dose now, since she is well; the dose will rise only if symptoms return, keeping exposure as low as effective.
Her Obstetric Team's View
Her obstetric clinician, contacted with her consent, agrees with continuing sertraline and will add a note to her prenatal record so that the delivery team knows.
Screening Later in Pregnancy
Her PHQ-9 will be repeated at every prenatal visit, with an Edinburgh Postnatal Depression Scale added after delivery.
Emotional Support
Ms. C. felt guilty about taking medicine while pregnant. I remind her that treating her depression is part of caring for her baby, since a well mother is better able to care for herself and her child.
Visit Frequency
I will see her monthly through pregnancy and every two weeks in the last month, when sleep and stress often change.
Coordination
With her consent, I inform her obstetric clinician and plan for the delivery team and pediatrician to know about her sertraline. We discuss the postpartum period, when relapse risk is highest, and plan follow-up at two and six weeks after delivery.
Nondrug Support
I refer her for psychotherapy during pregnancy and encourage sleep protection and support from her partner, both important for preventing postpartum depression.
Conclusion
For Ms. C., well on sertraline after severe recurrent depression, stopping medication in pregnancy carries a large, measured risk of relapse, while large cohort studies show no substantial increase in cardiac defects and at most a small absolute increase in persistent pulmonary hypertension of the newborn. Presented with these numbers, she chose to continue sertraline, with close monitoring, dose adjustment if needed and planning for the postpartum period.
References
Cohen, L. S., Altshuler, L. L., Harlow, B. L., Nonacs, R., Newport, D. J., Viguera, A. C., Suri, R., Burt, V. K., Hendrick, V., Reminick, A. M., Loughead, A., Vitonis, A. F., & Stowe, Z. N. (2006). Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment. JAMA, 295(5), 499-507. https://doi.org/10.1001/jama.295.5.499
Huybrechts, K. F., Bateman, B. T., Palmsten, K., Desai, R. J., Patorno, E., Gopalakrishnan, C., Levin, R., Mogun, H., & Hernandez-Diaz, S. (2015). Antidepressant use late in pregnancy and risk of persistent pulmonary hypertension of the newborn. JAMA, 313(21), 2142-2151. https://doi.org/10.1001/jama.2015.5605
Huybrechts, K. F., Palmsten, K., Avorn, J., Cohen, L. S., Holmes, L. B., Franklin, J. M., Mogun, H., Levin, R., Kowal, M., Setoguchi, S., & Hernández-Díaz, S. (2014). Antidepressant use in pregnancy and the risk of cardiac defects. New England Journal of Medicine, 370(25), 2397-2407. https://doi.org/10.1056/NEJMoa1312828
How this PMH 502 Week 8 example is structured
The PMH/502 Week 8 work usually closes with prescribing for children, older adults and pregnancy. This paper addresses a common, high-stakes decision in pregnancy, presenting risks on both sides in absolute terms and leaving the decision with the patient. Students search this week as PMH 502 Week 8, PMH502 Wk 8 or PMH/502 Wk 8; all three are the same assignment.
PMH/502 Week 8 questions, answered
What does PMH/502 Week 8 usually ask for?
Many sections close with psychotropic prescribing for special populations, including children, older adults and pregnant or breastfeeding people.
Is it safe to take sertraline in pregnancy?
Large cohort studies have not found a substantial increase in cardiac malformations with first-trimester antidepressant use, and the absolute risk of persistent pulmonary hypertension of the newborn is small, so sertraline is often continued when needed.
What happens if antidepressants are stopped in pregnancy?
In a prospective study, women with a history of depression who stopped antidepressants during pregnancy relapsed far more often than those who continued.
Write yours, or have the desk draft it
This paper is an original model document written by our desk, not a submitted student paper and not an official University of Phoenix document. Read it for the moves, then write your own to the instructions in your classroom. If you want one built to your exact prompt and rubric, the first custom sample is free and arrives in 24 to 48 hours.